Skip to main content

Rolapitant use while Breastfeeding

Medically reviewed by Drugs.com. Last updated on May 27, 2024.

Drugs containing Rolapitant: Varubi, Varubi IV

Rolapitant Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of rolapitant during breastfeeding. Because rolapitant and its metabolites are more than 99% bound to plasma proteins, the amount in milk is likely to be low; however, the binding of its major active metabolite is not known. If the mother requires rolapitant, it is not a reason to discontinue breastfeeding. However, consideration should be given to any chemotherapy the mother is receiving.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Rolapitant

CAS Registry Number

552292-08-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Antiemetics

Neurokinin-1 Receptor Antagonists

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.